N
Noriomi Matsumura
Researcher at Kindai University
Publications - 231
Citations - 8607
Noriomi Matsumura is an academic researcher from Kindai University. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 38, co-authored 195 publications receiving 6658 citations. Previous affiliations of Noriomi Matsumura include Kyoto University & Duke University.
Papers
More filters
Journal ArticleDOI
Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi,Masaki Mandai,Takafumi Ikeda,Manabu Minami,Atsushi Kawaguchi,Toshinori Murayama,Masashi Kanai,Yukiko Mori,Shigemi Matsumoto,Shunsuke Chikuma,Noriomi Matsumura,Kaoru Abiko,Tsukasa Baba,Ken Yamaguchi,Akihiko Ueda,Yuko Hosoe,Satoshi Morita,Masayuki Yokode,Akira Shimizu,Tasuku Honjo,Ikuo Konishi +20 more
TL;DR: The encouraging safety and clinical efficacy of nivolumab in patients with platinum-resistant ovarian cancer indicate the merit of additional large-scale investigations (UMIN Clinical Trials Registry UMIN000005714).
Journal ArticleDOI
IFN-γ From Lymphocytes Induces PD-L1 Expression and Promotes Progression of Ovarian Cancer
Kaoru Abiko,Noriomi Matsumura,Junzo Hamanishi,Naoki Horikawa,Ryusuke Murakami,Ken Yamaguchi,Yumiko Yoshioka,Tsukasa Baba,Ikuo Konishi,Masaki Mandai +9 more
TL;DR: The lymphocyte infiltration and the IFN-γ status may be the key to effective anti- PD-1 or anti-PD-L1 therapy in ovarian cancer.
Journal ArticleDOI
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells
Tsukasa Baba,Tsukasa Baba,P A Convery,Noriomi Matsumura,Noriomi Matsumura,Regina S. Whitaker,Eiji Kondoh,Eiji Kondoh,T Perry,Zhiqing Huang,Rex C. Bentley,Seiichi Mori,Shingo Fujii,Jeffrey R. Marks,Jeffrey R. Marks,Andrew Berchuck,Andrew Berchuck,Susan K. Murphy,Susan K. Murphy +18 more
TL;DR: Results show that CD133 expression in ovarian cancer is directly regulated by epigenetic modifications and support the idea thatCD133 demarcates an ovarian cancer-initiating cell population.
Journal ArticleDOI
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
Jin Peng,Junzo Hamanishi,Noriomi Matsumura,Kaoru Abiko,Kumuruz Murat,Tsukasa Baba,Ken Yamaguchi,Naoki Horikawa,Yuko Hosoe,Susan K. Murphy,Ikuo Konishi,Masaki Mandai +11 more
TL;DR: It is found that chemotherapy induces local immune suppression in ovarian cancer through NF-κB-mediated PD-L1 upregulation and a combination of chemotherapy and immunotherapy targeting the PD- L1/PD-1 signaling axis may improve the antitumor response and offers a promising new treatment modality against ovarian cancer.
Journal ArticleDOI
An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)
R Y-J Huang,Meng Kang Wong,Tuan Zea Tan,K.T. Kuay,A H C Ng,Vin Yee Chung,Y-S Chu,Noriomi Matsumura,H-C Lai,Y F Lee,W-J Sim,C Chai,E Pietschmann,Seiichi Mori,Seiichi Mori,Jeffrey Low,Mahesh Choolani,Jean Paul Thiery,Jean Paul Thiery +18 more
TL;DR: It is shown how a 33-gene EMT Signature can sub-classify an OC cohort into four EMT States correlating with progression-free survival (PFS) and concluded that the characterisation of intermediate EMT states provides a new approach to better define EMT.